Facioscapulohumeral muscular dystrophy (FSHD) is a genetic condition that affects muscle function, often making everyday tasks — like smiling or lifting one’s arms — difficult. For ...

An onslaught of new setbacks due to FSHD disease progression has left columnist Robin Stemple understandably anxious about ...

Adeno-associated virus (AAV)–mediated gene therapy was one of the focal points of this year's Muscular Dystrophy Association conference. Here, Barry Byrne, MD, PhD, University of Florida, speaks to ...

BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ...

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule.

Distinguished new members of the FSHD Society's Board of Directors bring expertise to help accelerate treatments and expand advocacy for the FSH muscular dystrophy community. Mel Hayes, a seasoned ...

candidate for myotonic dystrophy type 1 (DM1), and del-brax for facioscapulohumeral muscular dystrophy (FSHD). All three candidates are based on the same TfR1-targeting antibody component.

CNW/ - Springbok Analytics ( a leader in AI-powered muscle analysis, today announced its role in MOVE Peds, the first ...

Avidity Biosciences (RNA) announced del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy ...

The company’s pipeline includes not only the clinical programs for DM1 and DMD but also preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. This ...